Attitudes of US relapsing-remitting multiple sclerosis patients to current and emerging therapies
Less than 30% of surveyed relapsing-remitting multiple sclerosis (MS) patients in the USA indicate that they would request a switch to an emerging agent that matches a dosing, safety and efficacy profile similar to emerging and recently launched oral MS agents such as Merck KGaA (MRK: DE)/Serono/EMD Serono's oral cladribine (which has yet to gain approval in the USA) and Novartis' (NOVN: VX) Gilenya (fingolimod) which was recently cleared by the Food and |Drug Administration (The Pharma Letter September 24), according to a new report from advisory firm Decision Resources.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze